Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, and patient-, disease- and treatment-specific factors; and Integrate evidence-based strategies and best practices to recognize, mitigate, and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC